OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SCLX
Scilex Holding Company
There isn't enough reported data to score SCLX yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SCLX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
SCLX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SCLX PE Valuation
SCLX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 5.5x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over SCLX on the outlook, with more favorable profitability expectations.
SCLX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect SCLX to return to profit, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SCLX in the latest year-over-year earnings comparison.
SCLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.28 | — |
| Q3 2025 | -$31.88 | -$3.18 |
SCLX lost $31.88 per share over the past year, a bigger loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SCLX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SCLX on profitability, with a higher operating margin.
SCLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.6M | -23% |
| Q1 2026 | $8.6M | +72% |
| Q4 2025 | $4.8M | -68% |
| Q3 2025 | $10.6M | -27% |
| Q2 2025 | $9.9M | -40% |
| Q1 2025 | $5M | -54% |
| Q4 2024 | $14.9M | +11% |
| Q3 2024 | $14.4M | +43% |
SCLX's revenue has slid since its 2024 peak: $8M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -385% | -178 points |
| Q1 2026 | -373% | +184 points |
| Q4 2025 | -2318% | -2127 points |
| Q3 2025 | -1766% | -1628 points |
| Q2 2025 | -207% | -112 points |
| Q1 2025 | -558% | -379 points |
| Q4 2024 | -190% | -54 points |
| Q3 2024 | -138% | +246 points |
SCLX's operating margin was −385% last quarter, down 178 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with SCLX at up 271%.
SCLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.1M | -118% |
| Q3 2025 | $8.2M | +61% |
| Q1 2025 | $6M | -36% |
| Q4 2024 | $2.5M | +$7.9M |
| Q3 2024 | $5.1M | -13% |
| Q1 2024 | $9.4M | +$17.1M |
| Q3 2023 | $5.9M | +$6.2M |
| Q1 2023 | -$7.7M | -$6.9M |
SCLX usually generates cash, though not every quarter: the latest was −$1M, but it generated $20M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SCLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -23% | -115K shares |
| 1 year | -24% | -116K shares |
SCLX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SCLX Net Leverage
SCLX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SCLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 0.8 | Oversold |
SCLX's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SCLX PE vs Healthcare Sector
| Metric | SCLX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SCLX has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SCLX on trend strength, trading above more of its moving averages.
SCLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.77 | 44% below |
| 20 week MA | $5.09 | 69% below |
| 50 week MA | $7.45 | 79% below |
| 100 week MA | $10.2 | 85% below |
| 200 week MA | $62.2 | 97% below |
SCLX is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SCLX on returns for 2026, with the stronger performance.
SCLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $344.8 | $351.4 | +1.9% |
| 2022 | $351.4 | $117.3 | -67% |
| 2023 | $117.3 | $71.4 | -39% |
| 2024 | $71.4 | $13.7 | -81% |
| 2025 | $13.7 | $14.1 | +3.3% |
| 2026 YTD | $14.1 | $1.56 | -89% |
SCLX has finished lower in three of the last five years. It's down 89% so far in 2026.